Breaking News

Anixa Biosciences, MolGenie Find COVID Compounds Effective Against Omicron

Results of a genomic variant analysis indicate that the compounds in development should be effective against the Omicron variant.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Anixa Biosciences, Inc., a biotechnology company focused on treatment and prevention of cancer and infectious diseases, announced the results of a genomic variant analysis done with its partner, MolGenie, GmbH, on potential compounds to treat COVID-19. The data indicate that the compounds in development should be effective against the Omicron variant of SARS-CoV-2, in addition to the previously identified Delta variant of the virus.   Anixa and MolGenie are developing compounds for the potenti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters